BioSpace News Archive

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Blake Aftab, Ph.D., as Vice President of Research.

Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007)

TeamedOn International, Inc. and Applied Genetic Technologies Corporation announced a licensing agreement to advance gene therapy to treat X-linked retinoschisis, an inherited disease that causes loss of vision due to degeneration of the retina in males.

Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies.

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced the appointment of Tiago Girão to its Board of Directors.

Tiziana Life Sciences plc, announced that its former subsidiary, Accustem Sciences Limited, intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders.

Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial)

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was included in the moderate complexity automated NAAT class of molecular diagnostic technologies that were recognized for high diagnostic accuracy for tuberculosis testing by the World Health Organization (WHO)

LumiraDx announced today that it has received a reissued Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for LumiraDx SARS-CoV-2 RNA STAR Complete, a rapid, nucleic acid amplification method for high sensitivity, high throughput COVID-19 testing.